These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3191610)

  • 1. Are the traits for drug acetylation and oxidation co-inherited?
    Sardaş S; Karakaya AE; Idle JR
    Clin Genet; 1988 Aug; 34(2):143-4. PubMed ID: 3191610
    [No Abstract]   [Full Text] [Related]  

  • 2. Debrisoquin oxidation polymorphism in a Spanish population.
    Benítez J; LLerena A; Cobaleda J
    Clin Pharmacol Ther; 1988 Jul; 44(1):74-7. PubMed ID: 3391005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
    Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and drug metabolism: an Irish perspective.
    Holland P; Barry M; Feely J
    Ir J Med Sci; 1991 Feb; 160(2):54-6. PubMed ID: 1917424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Mikus G; Gross AS; Beckmann J; Hertrampf R; Gundert-Remy U; Eichelbaum M
    Clin Pharmacol Ther; 1989 May; 45(5):562-7. PubMed ID: 2498026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Narcotic analgesics and debrisoquine polymorphism.
    Lavrijsen KL; Heykants JJ
    Anesthesiology; 1989 Sep; 71(3):474-5. PubMed ID: 2570539
    [No Abstract]   [Full Text] [Related]  

  • 7. The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype.
    Bechtel YC; Joanne C; Grandmottet M; Bechtel PR
    Clin Pharmacol Ther; 1988 Oct; 44(4):408-17. PubMed ID: 3168393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The genetically determined polymorphism of metabolic oxidation of the sparteine-debrisoquin type].
    Piotrovskiĭ VK; Belolipetskaia VG
    Farmakol Toksikol; 1991; 54(6):60-6. PubMed ID: 1804700
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children.
    Evans WE; Relling MV; Petros WP; Meyer WH; Mirro J; Crom WR
    Clin Pharmacol Ther; 1989 May; 45(5):568-73. PubMed ID: 2721111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of serum concentrations of caffeine, 4-methylaminoantipyrine, sulfamethazine and debrisoquin following oral administration of these substances as a cocktail in type II diabetics before and after insulin therapy].
    Lautenschlager MT; Viktor S; Müller UA; Hoffmann A
    Pharmazie; 1996 Oct; 51(10):750-3. PubMed ID: 8999440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical aspects of the polymorphism of oxidation phenotype].
    Mrozikiewicz PM
    Pol Tyg Lek; 1992 Jul 6-13; 47(27-28):608-10. PubMed ID: 1488339
    [No Abstract]   [Full Text] [Related]  

  • 13. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymerase chain reaction and its potential as a pharmacokinetic tool.
    Heim MH
    Clin Pharmacokinet; 1992 Nov; 23(5):321-7. PubMed ID: 1362142
    [No Abstract]   [Full Text] [Related]  

  • 15. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.
    Taja-Chayeb L; González-Fierro A; Miguez-Muñoz C; Trejo-Becerril C; Cruz-Hernandez Ede L; Cantu D; Agundez JA; Vidal-Millan S; Gutierrez O; Dueñas-González A
    Pharmacogenet Genomics; 2011 Dec; 21(12):894-901. PubMed ID: 21946899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of antipyrine and sulfamethazine in patients recovered from dihydralazine-hepatitis.
    Siegmund W; Franke G; Baumgarten R; Fengler JD; Krüger R; Reichardt R
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):165-9. PubMed ID: 2714917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
    Philip PA; James CA; Rogers HJ
    Br J Clin Pharmacol; 1987 Dec; 24(6):827-9. PubMed ID: 3440103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylation and hydroxylation polymorphisms in type II diabetics with microvascular disturbances.
    Gawrońska-Szklarz B; Górnik W; Pawlik A; Kunicki P; Wójcicki J; Sitkiewicz D; Sych Z
    Eur J Clin Pharmacol; 1997; 51(6):431-5. PubMed ID: 9112055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylation and oxidation phenotypes in malignant lymphoma.
    Philip PA; Rogers HJ; Harper PG
    Cancer Chemother Pharmacol; 1987; 20(3):235-8. PubMed ID: 3677298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.